UKPDS and the Legacy Effect
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The United Kingdom Prospective Diabetes Study (UKPDS) continues to produce important evidence concerning the evolution of type 2 diabetes and its management. Two studies published in this issue of the Journal provide some answers to two questions of fundamental importance to patients with diabetes and to physicians alike. In one article, Holman et al. (UKPDS 80)1 provide data that confirm a so-called legacy effect associated with intensive glucose control in patients with type 2 diabetes, long after the cessation of randomized intervention. This finding provides a fitting parallel to the observations of the Diabetes Control and Complications Trial/Epidemiology of Diabetes . . .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Up to 25% of persons with T2D have already developed at least 1 microvascular complication by the time of diagnosis.40,41”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [40]
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Effect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
Goh, S.-Y., & Cooper, M. E. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1817 · Cited by 987
Self-citationLong-term follow-up after tight control of blood pressure in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Neil, H. A. W., & Matthews, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806359 · Cited by 762
Research works printed but not linked: 2
- 10.1056/nejmoa0806359 · DOI · Paper page
- 10.1056/nejmoa0806470 · DOI · Paper page
Cited by
Items 101–200 of 271
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
Lunati, M. E., Cimino, V., Bernasconi, D. P., Gandolfi, A., Morpurgo, P. S., Tinari, C., Lazzaroni, E., Baruffaldi, L., Muratori, M., Montefusco, L. B., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107040 · Cited by 36
Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus
Pok, E.-H., & Lee, W.-J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i39.14315 · Cited by 40
Wijesuriya, M., Fountoulakis, N., Guess, N. D., Banneheka, S. G., Vasantharajah, L., Gulliford, M. C., Viberti, G. C., Gnudi, L., & Karalliedde, J. J. (2017) · BMC Medicine · doi:10.1186/s12916-017-0905-6 · Cited by 37
“It is reasonable to suggest that reduction in risk with PLSM of dysglycaemia and hypertension, two conditions causally related to CVD, may translate over time into fewer cardiovascular events [19, 20].”
BackgroundPrimary and Secondary Prevention of Coronary Heart Disease
Gaziano, J. M., Ridker, P. M., & Libby, P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00049-4 · Cited by 34
Sia, H.-K., Kor, C.-T., Tu, S.-T., Liao, P.-Y., & Wang, J.-Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-81024-x · Cited by 33
Metabolic memory and diabetic nephropathy: Beneficial effects of natural epigenetic modifiers
Kushwaha, K., Sharma, S., & Gupta, J. (2020) · Biochimie · doi:10.1016/j.biochi.2020.01.007 · Cited by 36
Bansal, A., Balasubramanian, S., Dhawan, S., Leung, A., Chen, Z. B., & Natarajan, R. D. (2020) · Diabetes · doi:10.2337/db20-0382 · Cited by 34
Ried‐Larsen, M., Christensen, R., Hansen, K. B., Johansen, M. Y., Pedersen, M., Zacho, M., Hansen, L. S., Kofoed, K., Thomsen, K., Jensen, M. S., et al. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-009764 · Cited by 34
“25 26 In a recent review it was concluded that minor increases in light intensity physical activity could improve glycaemic control in healthy persons and patients with T2D.”
BackgroundInfluentialSamson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
for the Regeneration of Vital Myocardium in ST-Segment Elevation Myocardial Infarction by Erythropoietin (REVIVAL-3) Study Investigators, Steppich, B., Groha, P., Ibrahim, T., Schunkert, H., Laugwitz, K., Hadamitzky, M., Kastrati, A., & Ott, I. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-016-0464-3 · Cited by 30
“Moreover legacy or memory effects can influence clinical prognosis even long after cessation of drug administration [14].”
BackgroundXian, Y., Lin, Y., Cao, C., Li, L., Wang, J., Niu, J., Guo, Y., Sun, Y., Wang, Y., & Wang, W. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.05.034 · Cited by 30
Specialized pro-resolving mediators in diabetes: novel therapeutic strategies
Brennan, E. P., Mohan, M., Andrews, D. C., Bose, M., & Kantharidis, P. (2019) · Clinical Science · doi:10.1042/cs20190067 · Cited by 30
Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease
Zhang, C., Shi, Y., Liu, C., Sudesh, S. M., Zhao, H., Li, P., Liu, Q., Ma, Y., Shi, A., & Cai, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02273-4 · Cited by 32
“This phenomenon is referred to as a “legacy effect” or “metabolic memory” [85].”
Nahmias, A., Stahel, P., Xiao, C., & Lewis, G. F. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00100 · Cited by 31
Cognition in the Finnish Diabetes Prevention Study
Luchsinger, J. A., Lehtisalo, J., Lindström, J., Ngandu, T., Kivipelto, M., Ahtiluoto, S., Ilanne‐Parikka, P., Keinanen-Kiukaanniemi, S. M., Eriksson, J. G., Uusitupa, M. I. J., et al. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.023 · Cited by 26
“It is possible that interventions in persons with IGT may take a longer follow-up to show benefits, a phenomenon known as the legacy effect [17].”
BackgroundC‐peptide in diabetes: A player in a dual hormone disorder?
Dakroub, A. H., Dbouk, A., Asfour, A., Nasser, S. A., EL‐Yazbi, A. F., Sahebkar, A., Eid, A. A., Iratni, R., & Eid, A. H. (2024) · Journal of Cellular Physiology · doi:10.1002/jcp.31212 · Cited by 26
“Early exposure to hyperglycemia at diabetes onset is a risk factor for the development of long ‐ term vascular complications even after strict glycemic control (Chalmers & Cooper, 2008; Pirola et al., 2010).”
BackgroundBack to Wilson and Jungner: 10 Good Reasons to Screen for Type 2 Diabetes Mellitus
Sheehy, A. M., Coursin, D. B., & Gabbay, R. A. (2009) · Mayo Clinic Proceedings · doi:10.4065/84.1.38 · Cited by 32
Takizawa, F., Mizutani, S., Ogawa, Y., & Sawada, N. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.02.064 · Cited by 26
Menopausal Hormone Therapy and Risk of Diverticulitis
Jovani, M., Ma, W., Joshi, A. D., Liu, P., Nguyen, L. H., Cao, Y., Tam, I., Wu, K., Giovannucci, E. L., Chan, A. T., et al. (2019) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000054 · Cited by 26
Emerging uncertainty on the anti-aging potential of metformin
Keys, M. T., Hallas, J., Miller, R. A., Suissa, S., & Christensen, K. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102817 · Cited by 29
“Long-term follow-up showed that such cardiovascular effects persisted over 15 years, suggesting a legacy effect of early intervention in the treatment of hyperglycaemia (Holman et al., 2008; Chalmers and Cooper, 2008).”
Wang, X., & He, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107309 · Cited by 24
Kostis, W. J., Moreyra, A. E., Cheng, J., Dobrzynski, J. M., & Kostis, J. B. (2011) · Journal of clinical lipidology · doi:10.1016/j.jacl.2011.01.006 · Cited by 26
Diabetic dyslipidemia or ‘diabetes lipidus’?
Muačević‐Katanec, D., & Reiner, Ž. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.17 · Cited by 33
Lessons from CKD-Related Genetic Association Studies–Moving Forward
Limou, S., Vince, N., & Parsa, A. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09030817 · Cited by 23
The spectrum of antidiabetic actions of GLP-1 in patients with diabetes
Vilsbøll, T., Holst, J. J., & Knop, F. K. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.011 · Cited by 25
Nutrition, Epigenetic Mechanisms, and Human Disease
Maulik, N., & Maulik, G. (2010) · CRC Press eBooks · doi:10.1201/b10449 · Cited by 83
Ketoconazole enantiomer for the treatment of diabetes mellitus
Arakaki, R., & Welles, B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903381411 · Cited by 21
“Despite glycemic similarities post-UKPDS intervention, the legacy of previous treatment effect persists in favor of improved outcomes [3].”
BackgroundIs a legacy effect possible in IgA nephropathy?
Coppo, R. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft016 · Cited by 23
Chronic care model in primary care: can it improve health-related quality of life?
Lee, S. W. H., Aryani, F., Chua, S. S., Kok, L. C., Efendie, B., & Thomas, P. (2016) · Integrated Pharmacy Research and Practice · doi:10.2147/iprp.s92448 · Cited by 21
“Similarly, the UK Prospective Diabetes Study study has shown that a 1% reduction in HbA 1c will reduce microvascular and macrovascular complications over the next 10 years.(27) Lastly, the allocation of GP clinics to the usual care or intervention group could not be performed at random due to logistic reasons and also…”
BackgroundRusso, G. T., Nicolucci, A., Lucisano, G., Rossi, M. C., Ceriello, A., Prattichizzo, F., Manicardi, V., Rocca, A., Bartolo, P. D., Cosmo, S. D., et al. (2024) · Diabetes · doi:10.2337/db24-0166 · Cited by 22
Basics of Epigenetics and Role of Epigenetics in Diabetic Complications
Yamunadevi, A., Pratibha, R., Rajmohan, M., Mahendraperumal, S., & Ganapathy, N. (2021) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_771_20 · Cited by 19
“[16] 17-24] .”
New insights into myocardial glucose metabolism: surviving under stress
Patterson, B., Fields, A. V., & Shannon, R. P. (2009) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32832c4167 · Cited by 19
Metabolic surgery for type 2 diabetes: efficacy and risks
Halperin, F., & Goldfine, A. B. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32835edbb0 · Cited by 19
“Previous metabolic control imparts benefit extending years beyond the period of intervention as seen in the ‘legacy effect’ in the United Kingdom Prospective Diabetes Study (UKPDS) and STENO-2 trials [90,91].”
BackgroundMetabolism and chromatin dynamics in health and disease
Rodriguez, H., Rafehi, H., Bhave, M. R., & El‐Osta, A. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.004 · Cited by 19
The Legacy Effect in the Prevention of Cardiovascular Disease
Esmel, E. V., Naval-Álvarez, J., & Sacanella, E. (2020) · Nutrients · doi:10.3390/nu12113227 · Cited by 20
Jeon, J. Y., Kim, S. R., Kim, H. J., Kim, D. J., Lee, K. W., Lee, J.-D., & Han, S. J. (2016) · Medicine · doi:10.1097/md.0000000000005365 · Cited by 22
“Abbreviations: CI = confidence interval, ED = emergency department, eGFR = estimated glomerular filtration rate, HbA1c = glycated hemoglobin, HMA = severe hypoglycemia requiring medical assistance, mRS =modified Rankin Scale, NSH = nonsevere hypoglycemia, OHA = oral hypoglycemic agent, OR = odds…”
BackgroundWan, Q., Luo, S., Lu, Q., Guan, C., Zhang, H., & Deng, Z. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117319 · Cited by 18
Hypoglykämie und Herzrhythmusstörungen bei Patienten mit Diabetes Typ 2
Hanefeld, M., Ganz, X., & Nolte, C. (2014) · Herz · doi:10.1007/s00059-014-4086-1 · Cited by 18
Dutt, C., Salles, J. E. N., Joshi, S., Nair, T., Chowdhury, S., Mithal, A., Mohan, V., Kasliwal, R., Sharma, S., Tijssen, J. G. P., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s333787 · Cited by 19
“The glycemic legacy effect of early intervention in newly diagnosed patients in the UKPDS and individuals with impaired glucose tolerance in a diabetes prevention program has led to long-term reduction of cardiovascular–renal events and all-cause death.(25) The use of a system-wide strategy to diagnose and treat patie…”
BackgroundHung, Y., Lin, C., Wang, T.-Y., Chang, M., Sung, F., & Chen, C. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2444 · Cited by 18
“control decreased microvascular complications [2–5] and also demonstrated long-term macrovascular benefits, the so called ‘legacy effect’ [6].”
BackgroundEpigenetic Risk Profile of Diabetic Kidney Disease in High-Risk Populations
Xu, L., Natarajan, R. D., & Chen, Z. B. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1129-2 · Cited by 17
Wu, S., & Chen, W. (2021) · Aging · doi:10.18632/aging.203099 · Cited by 16
“This is supported by the “metabolic memory theory” [20] and “legacy effect” [21], which describe the benefits of early intensive treatment of hyperglycemia for preventing micro- and macro-vascular complications in type I and II diabetic patients.”
MethodTakao, T., Matsuyama, Y., Suka, M., Yanagisawa, H., & Kasuga, M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.005 · Cited by 15
Qian, X., Wang, J., Gong, Q., An, Y., Feng, X., He, S., Chen, X., Wang, W., Zhang, L., Hui, Y.-C., et al. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004419 · Cited by 15
“Second, the cohort was followed up for more than 30 years and revealed that time-limited lifestyle interventions could reduce the long-term cumulative incidence of all-cause death, cardiovascular death, and vascular complications [24].”
BackgroundGlycative Stress and Its Defense Machinery Glyoxalase 1 in Renal Pathogenesis
Hirakawa, Y., & Inagi, R. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010174 · Cited by 14
“glucose control is associated with fewer diabetic complications even years after treatment intervention for hyperglycemia ends [12,13].”
BackgroundMasi, L. N., Lotufo, P. A., Ferreira, F. M., Rodrigues, A. C., Serdan, T. D. A., Souza‐Siqueira, T., Braga, A. A., Saldarriaga, M. E. G., Alba‐Loureiro, T. C., Borges, F. T., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14731 · Cited by 15
“Diabetes complications occur due to long-term hyperglycemia exposure, even after a tight glycemic control regimen (Pirola et al., 2010), termed the metabolic memory or legacy effect (Chalmers & Cooper, 2008).”
Early diabetes screening in women with previous gestational diabetes: a new insight
Nabuco, A., Pimentel, S., Cabizuca, C. A., Rodacki, M., Finamore, D., Oliveira, M. M. D. S., & Zajdenverg, L. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0172-2 · Cited by 17
“Additionally, the early treatment of diabetes can prevent or delay microvascular end organ complications and reduce the risk of experiencing complications in subsequent pregnancies [19–23].”
BackgroundWan, E. Y. F., Yu, E. Y. T., Chen, J. Y., Wong, I. C. K., Chan, E. W., & Lam, C. L. K. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14157 · Cited by 16
“A legacy effect or metabolic memory attributed to intensive initial glucose control on CVD(32,33) may explain the inconsistent results in CVD.(32,33) Achieving a lower HbA1c target in newly diagnosed patients with diabetes may have long-lasting benefits in CVD prevention.”
ResultInfluentialHata, S., Ushigome, E., Hosomi, Y., Yoshimura, T., Takegami, M., Kitagawa, N., Tanaka, T., Hasegawa, G., Ohnishi, M., Tsunoda, S., et al. (2023) · Hypertension Research · doi:10.1038/s41440-022-01136-3 · Cited by 14
Correlation ofA2bARandKLF4/KLF15with Obesity-Dyslipidemia Induced Inflammation in Uygur Population
Wang, C., Ha, X., Li, W., Xu, P., Gu, Y., Wang, T., Wang, Y., Xie, J., & Zhang, J. (2016) · Mediators of Inflammation · doi:10.1155/2016/7015620 · Cited by 13
“Visceral adipose tissue, as one of the principal locations of the systemic inflammation response, plays an important role in the regulation of body energy metabolism [10].”
Interplay between epigenetic mechanisms and transcription factors in atherosclerosis
Aziz, M., Jandeleit-Dahm, K. A. M., & Khan, A. W. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117615 · Cited by 13
Das, A. K., Saboo, B., Chawla, R., Aravind, S. R., Rajput, R., Singh, A. K., Mukherjee, J. J., Jhingan, A. K., Shah, P., Deshmukh, V. C., et al. (2023) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01192-6 · Cited by 18
“Results from these trials indicate that tighter glycemic control prevented micro-vascular complications [38], with the ADVANCE trial demonstrating sustained glycemic control up to 5 years of SU therapy.”
BackgroundZhou, Y., Zhou, T., Chen, N., Zhou, G., Zhou, H., Li, X.-D., Wang, J., Bai, C.-F., Long, R., Xiong, Y.-X., et al. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i11.986 · Cited by 11
Lee, Y.-M., Lin, P., & Sia, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-66468-1 · Cited by 14
Metabolic Endoscopy: Development and Perspectives
Raddatz, D. (2019) · Digestion · doi:10.1159/000494428 · Cited by 12
Motherhood, Apple Pie, Hemoglobin A1C, and the DCCT
Trence, D., & Hirsch, I. B. (2012) · Endocrine Practice · doi:10.4158/ep11359.ra · Cited by 12
Abdel‐Rahman, N., Calderon‐Margalit, R., Cohen, A. D., Elran, E., Golan‐Cohen, A., Krieger, M., Paltiel, O., Valinsky, L. J., Ben‐Yehuda, A., & Manor, O. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025603 · Cited by 10
Centemero, M. P., Cherobin, J. C., Conti, K. V. F. D., Ohe, L. N., Mallmann, N., Abizaid, A., Farkouh, M. E., & Fuster, V. (2009) · Revista Brasileira de Cardiologia Invasiva · doi:10.1590/s2179-83972009000300018 · Cited by 11
Wan, E. Y. F., Yu, E. Y. T., Fung, C. S. C., Chin, W., Fong, D., Chan, A. K. C., & Lam, C. L. K. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.01.012 · Cited by 11
Raghavan, S., Liu, W. G., Berkowitz, S. A., Barón, A. E., Plomondon, M. E., Maddox, T. M., Reusch, J. E. B., Ho, P. M., & Caplan, L. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05848-5 · Cited by 9
Recent advances in glucose-lowering treatment to reduce diabetic kidney disease
Hanssen, N. M. J., Russell, N., & Cooper, M. E. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1041502 · Cited by 8
“This phenomenon has been termed by the DCCT group ‘metabolic memory’ and the ‘legacy effect’ by the UKPDS triallists [31,32].”
BackgroundSelf-citationAddressing Cardiovascular Risk in Patients With Type 2 Diabetes: Focus on Primary Care
STOLAR, M. W. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ec04e9 · Cited by 8
Moon, J. H., Jang, Y., Oh, T. J., & Jung, S. Y. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0159 · Cited by 8
“Previous exposure to obesity and future metabolic risk: obesity memory Metabolic memory and legacy effect describe the phenomenon of individuals experiencing the ongoing beneficial effects of improved and sustained glycemic control on diabetic complications [19,20].”
Hong, J. H., Kim, M., Min, K. W., Won, J. C., Kim, T. N., Lee, B., Kang, J. G., Kim, J. H., Park, J. H., Ku, B. J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15985 · Cited by 11
Boada, C. A. C., & Martínez-Moreno, J. M. (2013) · PubMed · doi:10.3305/nh.2013.28.sup2.6707 · Cited by 11
McRae, M., & Wang, C. C. L. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.11.012 · Cited by 8
Dwivedi, S., Chavan, A., & Paul, A. T. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103754 · Cited by 7
Kabadi, U. M. (2021) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2021.113007 · Cited by 10
Rasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 7
“These and other data(7,24) suggest that early and intensive management of hyperglycaemia has a ‘legacy' effect of long-term protection from both microvascular and macrovascular disease.(7,10,24)”
BackgroundChang, W., Xu, N., Kumagai, T., Iijima, R., Waki, K., Yamanaka, M., Nagura, M., Arai, S., Tamura, Y., Shibata, S., et al. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000485593 · Cited by 7
Korytkowski, M. T., Brooks, M. M., Lombardero, M., DeAlmeida, D. R., Kanter, J. E., Magaji, V., Orchard, T. J., & Siminerio, L. M. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814564183 · Cited by 7
Methods to address selection bias in post-trial studies of legacy effects were evaluated
Zhu, L., Bell, K., & Hayen, A. D. (2023) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2023.05.028 · Cited by 6
What is holding back glucometer use? -A comparative study of rural and urban India
Mishra, V., Nguyen, L., Wickramasinghe, N. S., & Islam, S. M. S. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102677 · Cited by 6
Baxter, M. A. (2014) · The British Journal of Diabetes · doi:10.15277/bjdvd.2014.026 · Cited by 6
Abdelgani, S., PUCKETT, C. L., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14383 · Cited by 6
The long-term benefits of early intensive therapy in chronic diseases—the legacy effect
Zoccali, C., Mallamaci, F., Tripepi, G. L., Fu, E. L., Stel, V. S., Dekker, F. W., & Jager, K. J. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad186 · Cited by 6
“As a matter of fact, early and intensive intervention can improve vascular function and structure, reducing the risk of long-term complications such as cardiovascular events and nephropathy [ 17 ].”
BackgroundEllahham (2010) · Clinical Epidemiology · doi:10.2147/clep.s15162 · Cited by 6
“The reduction occurred despite the intensive policy group having had similar glycemic control over the past 10 years; it may represent a “legacy effect” of earlier glycemic control.(24,38) Clinical studies have shown that patients with chronically elevated insulin levels due to insulin therapy have reduced insulin res…”
Yong, J., Tian, J., Zuo, H., Cao, J., Kong, H., Zhao, X., Yang, X., Zhang, H., He, Y., & Song, X. (2023) · Microvascular Research · doi:10.1016/j.mvr.2023.104493 · Cited by 5
The role of primary health care in primary and secondary prevention of diabetes
Erny-Albrecht, K. M., Bywood, P. T., & Oliver-Baxter, J. (2015) · Flinders Academic Commons (Flinders University) · Cited by 11
Watada, H., Kawakita, Y., Tanaka, K., Oh, A., Nishigaki, N., Nakajima, T., Fujikawa, K., & Akazawa, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01090-2 · Cited by 5
Coetzee, A., Hall, D. R., van de Vyver, M., & Conradie, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0282446 · Cited by 5
Laiteerapong, N., Fairchild, P. C., Nathan, A. G., Quinn, M. T., & Huang, E. S. (2016) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2016-000210 · Cited by 4
Kloecker, D. E., Davies, M. J., Pitocco, D., Khunti, K., & Zaccardi, F. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3634 · Cited by 4
Chao, A. M., Zhou, Y., Erus, G., Davatzikos, C. A., Cardel, M. I., Foster, G. D., & Wadden, T. A. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114228 · Cited by 4
Hoshuyama, T., Odashiro, K., Fukata, M., Maruyama, T., Saito, K., Wakana, C., 福光, ミ., & Fujino, T. (2015) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000000399 · Cited by 4
Ming-ming, C. A. O., & Tong, N. (2011) · Journal of Diabetes · doi:10.1111/j.1753-0407.2011.00133.x · Cited by 4
“Both the UKPDS3 and ACCORD6 found that insulin administration resulted in weight gain, which, in turn, aggravated insulin resistance and the risk of CVD.9 Investigation results and clinical experience indicate that patients receiving insulin therapy may well benefit more from a loosening of the standard glycemic contr…”
BackgroundMethodInfluentialCampos, K. Y., Sánchez-Gálvez, X., & Rivero-López, C. A. (2017) · Atención Familiar · doi:10.1016/j.af.2017.07.008 · Cited by 6
Sia, H., Kor, C., Tu, S., Liao, P.-Y., & Chang, Y.-C. (2021) · PeerJ · doi:10.7717/peerj.11005 · Cited by 4
Transforming Primary Care in Ireland: Information, Incentives, and Provider CapabilitiesPreprint
Ryan, P. (2011) · SSRN Electronic Journal · doi:10.2139/ssrn.1965995 · Cited by 4
Management of Type 2 Diabetes – Methods for Addition of Prandial to Basal Insulin
Rodbard, H. W., & Karolicki, B. (2014) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2014.10.02.124 · Cited by 4
Deng, S., Zhao, H.-Y., Chai, S., Sun, Y., Shen, P., Lin, H., & Zhan, S. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1369908 · Cited by 5
“Originally, the legacy effect refers to a phenomenon where an early and good glycemic control can yield long-lasting bene fi ts in reducing patients ’ risk of cardiovascular disease (CVD) even after the intensive therapy is discontinued (2, 4, 5).”
BackgroundTatti, P., Mauro, P. D., Masselli, L., Longobardi, A., & Barber, A. (2010) · Clinical ophthalmology · doi:10.2147/opth.s10273 · Cited by 4
Zhang, Z., Yang, L., & Cao, H. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383516 · Cited by 3
“Some post-trial analyses have presented the HbA 1c “ legacy effect ” ; that is, exposure to adverse glucose control had a prolonged in fl uence on the risk of future mortality (36).”
BackgroundGhouse, J., Blanche, P., Skov, M. W., Lind, B., Vaag, A. A., Kanters, J. K., Svendsen, J. H., Køber, L., OLESEN, M. S., Gerds, T. A., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa072 · Cited by 3
Do Aspirin and Clopidogrel Follow the Same Road Toward Prevention of Colorectal Cancer?
Jovani, M., & Chan, A. T. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.02.033 · Cited by 3
Lin, H., Huang, Y.-C., Hsieh, Y., & Chang, S.-H. (2025) · Ophthalmologica · doi:10.1159/000545941 · Cited by 2
““ Metabolic memory ” or “ legacy effect ” describes the susceptibility of diabetic patients to develop complications despite later-stage blood sugar control due to early hyperglycemia [29, 30].”
Optimizing Type 2 Diabetes Management: The Efficacy and Safety of Gliclazide in Clinical Practice
Mohan, V., Makkar, B. M., Saboo, B., Jagadisha, A., Chawla, M. S., Deshpande, N., Goyal, V. K., & Kapoor, R. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_50_25 · Cited by 3
GLP1-receptor-agonisták: antidiabetikumok kardiovaszkuláris előnnyel
Jermendy, G. (2020) · Cardiologia Hungarica · doi:10.26430/chungarica.2020.50.4.283 · Cited by 2
Lin, Y.-H., Lin, C., Huang, Y., Liu, P., & Lin, Y.-C. (2023) · Journal of Hospital Infection · doi:10.1016/j.jhin.2023.10.025 · Cited by 2
Shubrook, J. H. (2014) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2014.088 · Cited by 2
Metadata
- Authors
- Chalmers, J., & Cooper, M. E.
- Affiliations
- The University of Sydney (AU)
- Baker Heart and Diabetes Institute (AU)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-09
- Volume
- 359
- Issue
- 15
- Pages
- 1618-1620
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1966627775
- Cited by
- 263
- References
- 9
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 15 · 2023: 25 · 2022: 14 · 2021: 22 · 2020: 15 · 2019: 18 · 2018: 6 · 2017: 12 · 2016: 14 · 2015: 16 · 2014: 16 · 2013: 10 · 2012: 18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- legacy effects, tight glycemic control, type 2 diabetes, long-term glycemic control, diabetes management, UKPDS
- MeSH terms
- Antihypertensive Agents, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Glycated Hemoglobin, Humans, Hypertension, Hypoglycemic Agents, Insulin, Sulfonylurea Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.